PhaseBio Pharmaceuticals Inc. (PHAS) Prices 16M Share Common Offering at $3.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq climb as soft inflation dampens Fed rate hike expectations
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock
March 17, 2021 5:02 PM EDTPhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of... More
PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to 'Street High' $19 at Needham & Company
March 16, 2021 10:44 AM EDTNeedham & Company analyst Chad Messer raised the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) a 'Street High' to $19.00 (from $18.00) while maintaining a Buy rating.
... MorePhaseBio Pharmaceuticals Inc. (PHAS) Halted on LUDP, Up 12%
March 16, 2021 10:42 AM EDTPhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) Halted on LUDP, Up 12%
